Introduction
============

It is well known that the tumor cells can become resistance to the chemotherapeutics. Multidrug resistance (MDR) has been a major cause leading final failure of the tumor chemotherapy clinically (Bradley et al 1988). MDR is usually characterized by the over-expression of P-gp ([@b19-ijn-3-343]; [@b22-ijn-3-343]; [@b11-ijn-3-343]) that acts as an energy-dependent drug efflux pump and leads to a decrease in cytotoxic drug accumulation ([@b13-ijn-3-343]).

Unlike solid tumor, hematological malignant tumor can't be cured by surgical treatment. The main strategy to treat it is chemotherapy. Considering the importance of MDR in clinical hematological oncology, various kinds of P-gp-selective antagonisms have been developed to reverse P-gp-mediated MDR in vitro or in clinical trials. Undoubtedly, the reverse drugs can enhance the sensitization of the tumor to different chemotherapeutics in vivo or in vitro and thus resolve MDR to some extent ([@b14-ijn-3-343]; [@b26-ijn-3-343]; [@b1-ijn-3-343]; [@b24-ijn-3-343]). Except some drugs such as tetrandrine (Tet), cyclosporin A (CsA) and PSC 833, most P-gp-selective antagonisms can't be applied in large scale clinically because of their serious side effects on the pharmacokinetics of other accompanying chemotherapeutic drugs. Much effort has been devoted to the reversal of Tet in our laboratory in recent years and it was verified that Tet would be a potential reversal drugs in vivo and in vitro ([@b29-ijn-3-343]). Furthermore, one new strategy of target administering by drug carrier systems such as liposome (Alf and Jean-Pierre 2006), nanoparticle ([@b7-ijn-3-343]; [@b5-ijn-3-343]; [@b27-ijn-3-343]; [@b15-ijn-3-343]), and others, has been developed to enhance the efficiency of anticancer drug delivery. Nanomaterials are well known to have potential applications in various biomedical fields, such as disease diagnostics and therapeutics ([@b10-ijn-3-343]). They have attracted more and more attention to reverse MDR recently. It was reported that gold nanoparticles had been utilized for gene delivery ([@b21-ijn-3-343]). Moreover, some nanoparticles have been explored to illustrate the mechanisms of biochemical modulation and have potentially promising use in clinical cancer chemotherapy applications ([@b16-ijn-3-343]).

Magnetic nano-Fe~3~O~4~ could be used in the biomedicine areas because of their biocompatibility, simple preparation, and other unique properties ([@b30-ijn-3-343]; [@b17-ijn-3-343]). Fe~3~O~4~ nanoparticles were found readily to interact with proteins ([@b6-ijn-3-343]). It is reported that the trichloro-*s*-triazine (TsT) can be used as an easy linker to couple magnetic Fe~3~O~4~ nanoparticles with hydrophilic monomethoxy-poly (ethylene glycol) (mPEG), and the mPEG -- dopamine-coated nanoparticles were stable in buffer at various pH values greater than 7 or at the temperatures ranging from 25 °C to 70 °C. On the basis of these observations, it is possible to couple various hydrophilic macromolecules, including nucleotides and peptides, to iron oxide nanoparticles, which could be used for highly sensitive DNA sequence detection ([@b28-ijn-3-343]) and will contribute much to biomedical science.

Our recent reports have demonstrated that some anticancer drugs could be readily modified on some biocompatible nanomaterials, which could readily afford the sustained drug delivery for the target cancer cell lines and reduce the relevant toxicity towards normal cells and tissues ([@b17-ijn-3-343]; [@b20-ijn-3-343]). Thus, in this study, we have explored the combination of the high reactivity of nano-Fe~3~O~4~ or Au nanoparticles with daunomycin, one of the most important antitumor drugs in the treatment of acute leukemia clinically, to inhibit MDR of K562/A02 cells. The main point of this strategy is to increase the intracellular concentration of the targeted drug by the synergistic effect of nanoparticles. The reverse effects of nano-Fe~3~O~4~ and nano-Au towards K562 and K562/A02 cells have been investigated in this report.

Materials and methods
=====================

Cell lines and cell culture
---------------------------

K562 cells, derived from human leukemic cells of a chronic myeloid leukemia patient in blastic crisis, had been constantly preserved in our laboratory. K562/A02 cells (provided by Prof. C. Yang, Institute of Hematology, Chinese Academy of Medical Sciences and Peking Union Medical College, China) were incubated in the medium containing 1 μg/ml ADM for maintaining the resistant characteristics. K562/A02 cells were kept in medium without ADM for 2 weeks before using these cells. Both these two kinds of cell lines were cultured in a flask in RPMI 1640 medium (GIBCO, Carlsbad, CA, USA) supplemented with 10% fetal calf serum (FCS; GIBCO), 100 U/ml penicillin, and 100 μg/ml streptomycin at 37 °C, 5% CO~2~. K562/A02 cells were maintained in a complete RPMI 1640 medium containing 1 μg/ml adriamycin, and cultured for two weeks in drug-free medium prior to their use in each experiment.

Reagents
--------

Daunomycin (DNR) was purchased from Farmitalia (Italian). MTT was purchased from Sigma (St. Louis, MO, USA). PCR reagents kit was purchased from TaKaLa (China). TRI-zol reagent was purchased from Gibco/BRL, USA. MDR1 and β-actin primer were synthesized by Shanghai Biotechnology Company (China) and Invitrogen (Carlsbad, CA, USA). All reagents used in this study are analytical grade.

Preparation of drug-loaded nanoparticles
----------------------------------------

Nano-Fe~3~O~4~ and nano-Au were prepared by the electro-chemical deposition under oxidizing conditions (EDOC). Before applied in the present experiment, the magnetite nanoparticles were well-distributed in RPMI 1640 medium freshly added with 10% heat-inactivated FBS by using ultrasound treatment in order to obtain nano-Fe~3~O~4~ and nano-Au colloidal suspension. ADM conjugated with nano-Fe~3~O~4~ (nano-Fe~3~O~4~-ADM) or ADM conjugated with nano-Au (nano-Au-ADM) were prepared by mechanical absorption polymerization referring to previously reported ([@b12-ijn-3-343]; [@b3-ijn-3-343]). We also investigated the temperature effect and chose 37 °C or 4 °C for the polymerization process. Briefly, different concentrations (V/V), nano-Fe~3~O~4~ and nano-Au were respectively added under mechanical stirring to 200 μl of an aqueous medium with certain concentration of ADM that in the final nanoparticle and cell suspension was 50 μmol/l (pH 7.4). At different temperatures (37 °C, 4 °C), the overall polymerization process lasted for 24 h.

Cytotoxicity assays
-------------------

K562 and K562/A02 cells (2 × 10^4^ cells per well) in log phase were incubated into 96-well flat-bottomed plates (Costar, Charlotte, NC) respectively. Different concentrations of DNR, nano-Fe~3~O~4~ and nano-Au were added into these cells alone and cultured for 48 h to measure their cytotoxicity. On the basis of these results, different concentrations of DNR, nano-Fe~3~O~4~ and nano-Au were combined to find the best combination that the compound will kill the tumor cells most. After incubation for 48 h, MTT solution (20 μl at 5 mg/ml) was added to each well and incubated for 4 h, followed by reading the optical density value (*A*) at 540 nm using a plate reader (Model 550, BIO-RAD, Japan) to measure the amount of cell proliferation and/or killing. The inhibition ratio (IR) of cells was determined as follows: (1-*A* of tests cells/*A* of blank control) ×100%. Each assay was repeated at least three times.

DNR accumulation in K562/A02 cells and K562/A02 cells apoptosis
---------------------------------------------------------------

Briefly, 1 × 10^6^ cells were incubated with DNR (10 mg/L) in the presence or absence of nano-Fe~3~O~4~ (5.0 × 10^−7^ M) or nano-Au (2.0 × 10^−8^ M). After incubation for 48 h, cells were harvested and washed twice in ice-cold PBS and the amount of DNR accumulated in K562/A02 cells was determined by measuring the cell-associated fluorescence emission (480 nm) using flow cytometry (FACS Calibar, Becton -- Dickinson, USA) according to a previously descried method ([@b23-ijn-3-343]). Briefly, 100 pL cell suspensions were treated with 5 pL Annexin V-FITC for 30 min in the dark, and the sample were analyzed with flow cytometry. The apoptosis of several subgroup K562/A02 cells was measured by flow cytometry again to further identify the cytotoxicity of DNR with nano-Fe~3~O~4~ or nano-Au.

Confocal fluorescence microscopic studies
-----------------------------------------

50 mg/L DNR and 5.0 × 10^−7^ M nano-Fe~3~O~4~ or 2.0 × 10^−8^ M nano-Au magnetic solution were injected into a cell culture for incubation. In a control experiment, only DNR was injected into a cell culture for incubation. The culture was detected using a confocal fluorescence microscope (Leica TCS SP2) after incubating for 30 min. The freshly prepared cell culture was dropped on a rigorously cleaned glass plate immediately before the measurement. The excitation wavelength of the fluorescence was 480 nm.

RT-PCR study
------------

The several subgroup K562/A02 cells (above) were centrifuged by 1000 rpm for 5 min and collected. Total cellular RNA was extracted using the TRI-zol reagent as described by the manufacturer. One microgram of RNA was used for cDNA synthesis employing avian myeloblastosis virus (AMV) reverse transcriptase and oligo dT as the primer. cDNA was amplified with specific primers for MDR1. β-actin was used as an internal control to confirm successful cDNA synthesis. For MDR1 and β-actin, the amplify conditions as follows: 94 °C 30 sec, 56 °C 30 sec, 72 °C 1 min, 30 cycles. Primer sequences were as follows: MDR1 (437 bp) sense: 5′-TGG TTT GAT GTG CAC GAT GTT GGG-3′, antisense: 5′-AGA TCA GCA GGA AAG CAG CAC CTA-3′, β-actin (661 bp) sense: 5′-TGA CGG GGT CAC CCA CAC TGT GCC CAT CTA-3′, antisense: 5′-CTA GAA GCA TTT GCG GTG GAC GAT GGA GGG-3′ ([@b25-ijn-3-343]). PCR products were separated on 1.5% agarose gels. The band intensities on gels photographs were directly quantitated by ImagerMaster VDS image analysis (Pharmacia Biotech, USA), and the target/control ratios were calculated.

Results
=======

Growth rates of K562 and K562/A02 cells by MTT assay
----------------------------------------------------

We have examined the cytotoxic activity of DNR, nano-Fe~3~O~4~ or nano-Au alone to K562 cells and its Pgp-overexpression MDR counterparts-K562/A02. K562/A02 was significantly resistant to DNR: 50% inhibiting concentration (IC~50~) values after incubation for 48 h was 23.23 mg/L, which is 76-fold higher than K562 cells, while the IC~50~ values after incubation for 48 h of K562 cells was 0.307 mg/L. The growth inhibition curves of two cell lines to DNR were shown in [Figure 1](#f1-ijn-3-343){ref-type="fig"}. It was noted that nano-Fe~3~O~4~ or nano-Au themselves alone could hardly inhibit K562/A02 and K562 proliferation when their doses were between 2.0 × 10^−9^ M to 1.0 × 10^−6^ M (*P* \> 0.05), which also confirmed their good biocompatibility. In another experiment, we chose DNR in concentration of 10 mg/L, 20 mg/L, and 0.05 mg/L, 0.1 mg/L (smaller than IC~50~ to K562/A02 and K562, respectively) combined with different concentration of nano-Fe~3~O~4~ or nano-Au to find the optimum combination condition which affected most tumor cells. It was observed that nano-Fe~3~O~4~ or nano-Au combining with DNR could inhibit two cell lines proliferation significantly (*P* \< 0.001). 5.0 × 10^−7^ M nano-Fe~3~O~4~ or 2.0 × 10^−8^ M nano-Au did the best in K562/A02, while 2.5 × 10^−7^ M nano-Fe~3~O~4~ or 1.0 × 10^−8^ M nano-Au did the best in K562 (as shown in [Figures 2](#f2-ijn-3-343){ref-type="fig"}, [3](#f3-ijn-3-343){ref-type="fig"}).

Tumor cells apoptosis
---------------------

Based on these observations, it appeared that DNR combining with nano-Fe~3~O~4~ or nano-Au could efficiently increase the apoptosis ratio of K562/A02 cells. The flow cytometry results show that nano-Fe~3~O~4~ or nano-Au themselves can hardly induce the apoptosis of K562/A02 cells. 12.57% apoptosis of K562/A02 cells was observed under DNR alone, while 32.76% and 29.38% apoptosis of K562/A02 cells were observed when the K562/A02 cells were treated with DNR in combination with nano-Fe~3~O~4~ or nano-Au ([Figure 4](#f4-ijn-3-343){ref-type="fig"}).

The intracellular free DNR concentration
----------------------------------------

The intracellular DNR concentration of the K562/A02 cells was explored by flow cytometry. Compared with that treated with DNR alone, the intracellular DNR concentration of the K562/A02 cells were found to increase by 71% and 51%, respectively when the K562/A02 cells were treated with DNR in combination with nano-Fe~3~O~4~ and nano-Au, respectively. Similar observations were also illustrated through confocal fluorescent microscope ([Figure 5](#f5-ijn-3-343){ref-type="fig"}). Considering that the anticancer drug daunorubicin is a fluorescent molecule while the relevant nanoparticles have no fluorescence, our observations of the laser confocal fluorescence microscopy further confirm the synergistic effect of these nanoparticles on the cellular uptake of daunorubicin.

RT-PCR
------

Additionally, our RT-PCR studies showed that these two kinds of nanoparticles themselves could not lower the MDR1 gene expression of the K562/A02 cells, but they could down regulate the MDR1 gene level when combined with DNR. K562 cells were negative in MDR1 gene expression. Computer-assisted image analysis showed that the ratios of MDR1/β-actin band intensities were as follows: Nano-Fe~3~O~4~: 0.793 ±0.03, Nano-Au: 0.770 ± 0.033, Nano-Fe~3~O~4~ with DNR: 0.619 ± 0.034 (*P* \< 0.01) and Nano-Au with DNR: 0.635 ± 0.041 (*P* \< 0.01), where the descent rate were 23.3% and 21.6%, respectively (as shown in Table 3 and [Figure 6](#f6-ijn-3-343){ref-type="fig"}).

Discussion
==========

As described above, we have demonstrated that nanoparticles themselves can not reverse MDR-mediated resistance in K562/A02 cells, but they did if combined with certain chemotherapeutics such as DNR. However, it is reported that nano-Fe~3~O~4~ with better histocompatibililty to human body was suitable to prepare some materials imbedded in human body ([@b8-ijn-3-343]; [@b9-ijn-3-343]). Our observations indicate that nanoparticles themselves can not inhibit the growth of K562/A02 and K562 cells or induce their apoptosis. In our studies, we choose DNR with 10 mg/L or 20 mg/L and 0.05 mg/L or 0.1 mg/L to K562/A02 and K562 cells, respectively, which are smaller than IC~50~ of DNR, to combine different volume fraction of nanoparticles ranging from 2.0 × 10^−9^ M to 1.0 × 10^−6^ M so that they can interact with each other with water-bath at 50 °C for 30 min, following by standing to stay overnight. Our observations indicate that the presence of nano-Fe~3~O~4~ could enhance the cytotoxic effect of DNR to K562/A02 and K562 cells, having significant difference with DNR alone group (*P* \< 0.05). To K562/A02 cells, the effective combination, composed by 5.0 × 10^−7^ M nano-Fe~3~O~4~ or 2.0 × 10^−8^ M nano-Au and 10 mg/L DNR, could efficiently induce more K562/A02 cells apoptosis. These results may be attributed to that these nanoparticles could readily interact with DNR and form so-called conjugated nanocomposites, which could facilitate the cellular uptake of DNR and thus enhance the cytotoxic effect of K562/A02 cells. MTT and confocal fluorescent microscope studies also indicate that these functionalized nanoparticle could efficiently strengthen DNR lethal effect to target cancer cells and increase the intracellular accumulation of DNR. Meanwhile, we also find the non-specific cytotoxocity of these nanoparticles was similar for both the parent tumor cell line and its MDR counterpart ([Table 1](#t1-ijn-3-343){ref-type="table"}) which suggests that the relevant nanoparticles conjugated with DNR may exert its MDR-reversal activity via down-regulation of MDR gene transcription of K562/A02 cells.

In summary, we have demonstrated that the functional nanoparticles could help DNR entering K562/A02 and K562 cells and increase the intracellular accumulation of DNR.

Although the relative mechanisms need to be explored further, the conjugated nanocomposites could have promising application to inhibit the drug resistant and facilitate the target drug delivery in the relevant cancer chemotherapy.
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![Effect of the different concentrations of daunomycin (DNR) on growth inhibitiom rates of K562/A02 cells (**A**) and K562 cells (**B**) by MTT assay.](ijn-3-343f1){#f1-ijn-3-343}

![Growth inhibiting rate of daunomycin (DNR) with or without nanoparticle treated-K562/A02 cells (48 h).\
**Notes:** P \< 0.05, compared to DNR without nanoparticle treated-K562/A02 cells (single factor analysis of variance); ^1^P \< 0.01, compared with DNR without nanoparticle treated-K562/A02 cells (single factor analysis of variance).](ijn-3-343f2){#f2-ijn-3-343}

![Growth inhibiting rate of daunomycin (DNR) with or without nanoparticle treated-K562 cells (48 h).\
**Notes:** P \< 0.05, compared with DNR without nanoparticle treated-K562 cells (single factor analysis of variance); ^1^P \< 0.01, compared with DNR without nanoparticle treated-K562 cells (single factor analysis of variance); ^2^P \> 0.05, compared with DNR without nanoparticle treated-K562 cells (single factor analysis of variance).](ijn-3-343f3){#f3-ijn-3-343}

![The apoptosis of K562/A02 cells under daunomycin (DNR) with and without nanoparticles. K562/A02 cells (**A**--**D**) were incubated with Nano-Fe~3~O~4~ (5.0 × 10^−7^ M) (**B**), Nano-Au (2.0 × 10^−8^ M) (**C**), DNR (10 mg/L) (**D**) and nothing (**A**), respectively, and K562/A02 cells (**E**--**F**) were incubated with DNR (10 mg/L) in the presence of Nano-Fe~3~O~4~ (5.0 × 10^−7^ M) (**E**) or Nano-Au (2.0 × 10^−8^ M) (**F**) at 37 °C for 48 h.](ijn-3-343f4){#f4-ijn-3-343}

![Effect of nanoparticle on the intracellular accumulation of daunomycin (DNR) in K562/A02 cells (×1000). K562/A02 (**A**--**C**) and K562 (**D**--**F**) cells were incubated with DNR (50 mg/L) in the absence (**A, D**) or the presence of Nano-Fe~3~O~4~ (5.0×10^−7^ M) (**B**, **E**) or Nano-Au (2.0 × 10^−8^ M) (C, F) at 37 °C for 30 min. The cells were observed and photographed under a confocal fluorescent microscope.](ijn-3-343f5){#f5-ijn-3-343}

![The MDR1 mRNA level of K562/A02 cells with nanoparticles (5.0 × 10^−7^ M Nano-Fe~3~O~4~ or 2.0 × 10^−8^ M Nano-Au) in the absence or presence of DNR (10 mg/L) Lane:1, marker; 2, K562 (negative control); 3, K562/A02 (positive control); 4, Nano-Fe~3~O~4~; 5, Nano-Au; 6, DNR with Nano-Fe~3~O~4~; 7, DNR with Nano-Au.](ijn-3-343f6){#f6-ijn-3-343}

###### 

The MDR1 mRNA level of K562/A02 cells with nanoparticle in the absence or presence of DNR (at 48 h) (n = 3)

  Groups             Positive control   Nano-Fe~3~O~4~   Nano-Au         DNR with Nano-Fe~3~O~4~                                   DNR with Nano-Au
  ------------------ ------------------ ---------------- --------------- --------------------------------------------------------- ---------------------------------------------------------
  MDR1/β-actin       0.809 ± 0.033      0.793 ± 0.037    0.770 ± 0.040   0.619 ± 0.042[\*](#tfn1-ijn-3-343){ref-type="table-fn"}   0.635 ± 0.050[\*](#tfn1-ijn-3-343){ref-type="table-fn"}
  descent rate (%)                      1.90 ± 0.069     4.57 ± 0.072    23.33 ± 0.069                                             21.60 ± 0.035

**Notes:** *P* \< 0.01, compared with K562/A02 cells (single factor analysis of variance).
